Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 15

1.

Insights into Orphan Nuclear Receptors as Prognostic Markers and Novel Therapeutic Targets for Breast Cancer.

Aesoy R, Clyne CD, Chand AL.

Front Endocrinol (Lausanne). 2015 Aug 7;6:115. doi: 10.3389/fendo.2015.00115. eCollection 2015. Review.

2.

Nuclear receptor 4A (NR4A) family - orphans no more.

Safe S, Jin UH, Morpurgo B, Abudayyeh A, Singh M, Tjalkens RB.

J Steroid Biochem Mol Biol. 2016 Mar;157:48-60. doi: 10.1016/j.jsbmb.2015.04.016. Epub 2015 Apr 23.

3.

Therapeutic potential of targeting the oncogenic SHP2 phosphatase.

Zeng LF, Zhang RY, Yu ZH, Li S, Wu L, Gunawan AM, Lane BS, Mali RS, Li X, Chan RJ, Kapur R, Wells CD, Zhang ZY.

J Med Chem. 2014 Aug 14;57(15):6594-609. doi: 10.1021/jm5006176. Epub 2014 Jul 28.

4.

Minireview: role of orphan nuclear receptors in cancer and potential as drug targets.

Safe S, Jin UH, Hedrick E, Reeder A, Lee SO.

Mol Endocrinol. 2014 Feb;28(2):157-72. doi: 10.1210/me.2013-1291. Epub 2013 Dec 2. Review.

5.

Nuclear receptor small heterodimer partner in apoptosis signaling and liver cancer.

Zhang Y, Wang L.

Cancers (Basel). 2011 Jan 5;3(1):198-212. doi: 10.3390/cancers3010198.

6.

Loss of SHP-2 activity in CD4+ T cells promotes melanoma progression and metastasis.

Zhang T, Guo W, Yang Y, Liu W, Guo L, Gu Y, Shu Y, Wang L, Wu X, Hua Z, Ke Y, Sun Y, Shen Y, Xu Q.

Sci Rep. 2013 Oct 3;3:2845. doi: 10.1038/srep02845.

7.

Targeting protein tyrosine phosphatase SHP2 for the treatment of PTPN11-associated malignancies.

Yu B, Liu W, Yu WM, Loh ML, Alter S, Guvench O, Mackerell AD Jr, Tang LD, Qu CK.

Mol Cancer Ther. 2013 Sep;12(9):1738-48. doi: 10.1158/1535-7163.MCT-13-0049-T. Epub 2013 Jul 3.

8.

The lipophilic bullet hits the targets: medicinal chemistry of adamantane derivatives.

Wanka L, Iqbal K, Schreiner PR.

Chem Rev. 2013 May 8;113(5):3516-604. doi: 10.1021/cr100264t. Epub 2013 Feb 25. Review. No abstract available.

9.

Anti-tumor activity of a novel HS-mimetic-vascular endothelial growth factor binding small molecule.

Basappa., Sugahara K, Thimmaiah KN, Bid HK, Houghton PJ, Rangappa KS.

PLoS One. 2012;7(8):e39444. doi: 10.1371/journal.pone.0039444. Epub 2012 Aug 15. Erratum in: PLoS One. 2012;7(10):doi/10.1371/annotation/a685ce21-d7a1-4a5b-8fe8-734a071d53cd.

11.

Ligand-dependent regulation of the activity of the orphan nuclear receptor, small heterodimer partner (SHP), in the repression of bile acid biosynthetic CYP7A1 and CYP8B1 genes.

Miao J, Choi SE, Seok SM, Yang L, Zuercher WJ, Xu Y, Willson TM, Xu HE, Kemper JK.

Mol Endocrinol. 2011 Jul;25(7):1159-69. doi: 10.1210/me.2011-0033. Epub 2011 May 12.

12.

Role of nuclear receptor SHP in metabolism and cancer.

Zhang Y, Hagedorn CH, Wang L.

Biochim Biophys Acta. 2011 Aug;1812(8):893-908. doi: 10.1016/j.bbadis.2010.10.006. Epub 2010 Oct 20. Review.

13.

Insights into the binding mode and mechanism of action of some atypical retinoids as ligands of the small heterodimer partner (SHP).

Cellanetti M, Gunda V, Wang L, Macchiarulo A, Pellicciari R.

J Comput Aided Mol Des. 2010 Nov;24(11):943-56. doi: 10.1007/s10822-010-9386-9. Epub 2010 Sep 30.

14.

Novel polymorphisms of nuclear receptor SHP associated with functional and structural changes.

Zhou T, Zhang Y, Macchiarulo A, Yang Z, Cellanetti M, Coto E, Xu P, Pellicciari R, Wang L.

J Biol Chem. 2010 Aug 6;285(32):24871-81. doi: 10.1074/jbc.M110.133280. Epub 2010 Jun 1.

15.

Targeting protein tyrosine phosphatases for anticancer drug discovery.

Scott LM, Lawrence HR, Sebti SM, Lawrence NJ, Wu J.

Curr Pharm Des. 2010 Jun;16(16):1843-62. Review.

Supplemental Content

Support Center